Therefore, the decrease in the proportion of CD11b+CD11c+ myeloid cells might as well facilitate MET-1 tumor cell survival and progression independently of the increase in the tumor immunosuppressive microenvironment. The gene discussed is ITGAM; the disease is neoplasm.